These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 10428937

  • 1. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
    Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
    [Abstract] [Full Text] [Related]

  • 2. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.
    Johnson AP, Warner M, Livermore DM.
    J Antimicrob Chemother; 2000 Feb; 45(2):225-30. PubMed ID: 10660506
    [Abstract] [Full Text] [Related]

  • 3. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
    Lundstrom TS, Sobel JD.
    Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R, Rouse MS, Piper KE, Steckelberg JM.
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
    [Abstract] [Full Text] [Related]

  • 5. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ, Hershberger E, Moldovan T, Grucz RG.
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.
    Cercenado E, García-Garrote F, Bouza E.
    J Antimicrob Chemother; 2001 Jan; 47(1):77-81. PubMed ID: 11152434
    [Abstract] [Full Text] [Related]

  • 7. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
    Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, Hutchinson DK, Barbachyn MR, Brickner SJ.
    Antimicrob Agents Chemother; 1996 Apr; 40(4):839-45. PubMed ID: 8849237
    [Abstract] [Full Text] [Related]

  • 8. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE, Fritsche TR, Sader HS, Jones RN.
    Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
    [Abstract] [Full Text] [Related]

  • 9. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).
    Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ, Jones RN.
    Clin Microbiol Infect; 2002 Dec; 8(12):791-800. PubMed ID: 12519352
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
    Wagenlehner FM, Lehn N, Witte W, Naber KG.
    Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
    [Abstract] [Full Text] [Related]

  • 11. Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.
    Zurenko G, Bien P, Bensaci M, Patel HN, Thorne G.
    Ann Clin Microbiol Antimicrob; 2014 Sep 20; 13():46. PubMed ID: 25238753
    [Abstract] [Full Text] [Related]

  • 12. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients.
    Rolston KV, Kapadia M, Tarrand J, Coyle E, Prince RA.
    Int J Antimicrob Agents; 2013 Jun 20; 41(6):516-20. PubMed ID: 23481658
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities in new oxazolidinone antimicrobial agents against enterococci.
    Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC.
    Antimicrob Agents Chemother; 1996 Jul 20; 40(7):1745-7. PubMed ID: 8807077
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods.
    Tubau F, Fernández-Roblas R, Liñares J, Martín R, Soriano F.
    J Antimicrob Chemother; 2001 May 20; 47(5):675-80. PubMed ID: 11328783
    [Abstract] [Full Text] [Related]

  • 15. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
    Aktaş G, Bozdoğan B, Derbentli S.
    Mikrobiyol Bul; 2012 Jul 20; 46(3):359-65. PubMed ID: 22951648
    [Abstract] [Full Text] [Related]

  • 16. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW.
    Antimicrob Agents Chemother; 1998 Mar 20; 42(3):721-4. PubMed ID: 9517963
    [Abstract] [Full Text] [Related]

  • 17. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD.
    Diagn Microbiol Infect Dis; 2009 Dec 20; 65(4):404-13. PubMed ID: 19913683
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF.
    Int J Antimicrob Agents; 2015 Dec 20; 46(6):674-81. PubMed ID: 26541881
    [Abstract] [Full Text] [Related]

  • 19. The in-vitro activity of linezolid (U-100766) and tentative breakpoints.
    Wise R, Andrews JM, Boswell FJ, Ashby JP.
    J Antimicrob Chemother; 1998 Dec 20; 42(6):721-8. PubMed ID: 10052894
    [Abstract] [Full Text] [Related]

  • 20. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
    Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN.
    Diagn Microbiol Infect Dis; 2002 May 20; 43(1):65-73. PubMed ID: 12052631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.